IMPEDIMED LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.086 AUD | -4.44% |
|
-7.53% | -40.69% |
| 04-17 | Impedimed Implements Organizational Changes; Makes Strategy Chief, COO Redundant | MT |
| 04-17 | Ord Minnett Starts ImpediMed at Speculative Buy, Price Target is AU$0.16 | MT |
| Sales 2024 * | 10.87M 7.1M 568M | Sales 2025 * | 19.14M 12.5M 1B | Capitalization | 174M 114M 9.1B |
|---|---|---|---|---|---|
| Net income 2024 * | -21M -13.72M -1.1B | Net income 2025 * | -14M -9.14M -732M | EV / Sales 2024 * | 13.7 x |
| Net cash position 2024 * | 24.71M 16.14M 1.29B | Net cash position 2025 * | 13.87M 9.06M 725M | EV / Sales 2025 * | 8.37 x |
| P/E ratio 2024 * |
-9.01
x | P/E ratio 2025 * |
-14.1
x | Employees | 76 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 85.74% |
More Fundamentals
* Assessed data
More news
Latest transcript on ImpediMed Limited
| 1 day | -4.44% | ||
| 1 week | -7.53% | ||
| Current month | -6.52% | ||
| 3 months | -33.85% | ||
| 6 months | -31.20% | ||
| Current year | -40.69% |
1 week
0.09
0.09
1 month
0.090.11
Current year
0.080.16
1 year
0.080.24
3 years
0.050.24
5 years
0.030.35
10 years
0.031.82
| Managers | Title | Age | Since |
|---|---|---|---|
Parmjot Bains
CEO | Chief Executive Officer | - | 01-07 |
McGregor Grant
DFI | Director of Finance/CFO | - | 27/09/23 |
Steven Chen
CTO | Chief Tech/Sci/R&D Officer | - | 25/09/23 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Parmjot Bains
CEO | Chief Executive Officer | - | 01-07 |
McGregor Grant
DFI | Director of Finance/CFO | - | 27/09/23 |
| Chairman | - | 27/09/23 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 0.086 | -4.44% | 1,396,833 |
| 24/04/24 | 0.09 | 0.00% | 900,191 |
| 23/04/24 | 0.09 | 0.00% | 639,897 |
| 22/04/24 | 0.09 | -3.23% | 808,812 |
| 19/04/24 | 0.093 | -2.11% | 1,210,425 |
Delayed Quote Australian S.E., April 26, 2024 at 07:10 am
More quotes
ImpediMed Limited is an Australia-based medical software technology company. The Company is engaged in the development, manufacture, and sale of bioimpedance spectroscopy (BIS) systems and software services with a focus on the early detection of lymphoedema and heart failure. It measures, monitors and manages fluid status and tissue composition using BIS. The Companyâs SOZO digital health platform uses BIS technology to measure and track critical information about the human body to aid clinicians in managing chronic disease and maximizing patient health. Its SFB7 measures fluid status and tissue composition for clinical and research applications. It offers ImpediVET, a single-channel, tetrapolar BIS device that measures fluid status and tissue composition for veterinary applications from laboratory research to clinic. SOZO applications include L-Dex Analysis for Lymphedema, BodyComp Analysis, Segmental BodyComp analysis, and HF-Dex analysis for heart failure.
Calendar
29/04/2024
- March 2024 Sales and Revenue Release
Trading Rating
Investor Rating
ESG Refinitiv
C
Sell
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
0.086
AUD
Average target price
0.176
AUD
Spread / Average Target
+104.67%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -40.69% | 113M | |
| +8.07% | 219B | |
| +6.59% | 183B | |
| +11.26% | 133B | |
| +26.57% | 108B | |
| +13.35% | 52.02B | |
| -0.62% | 48.2B | |
| -0.93% | 40.37B | |
| +11.54% | 39.35B | |
| +26.76% | 32.03B |
- Stock Market
- Equities
- IPD Stock
